Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow

Objective:To retrospectively investigate enhancement patterns of hepatocellular carcinoma (HCC) and dysplastic nodule (DN) in the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced MRI in relation to histological grading and portal blood flow.Methods:Sixty-nine consecutive patients with 83 histologically proven HCCs and DNs were studied. To assess Gd-EOB-DTPA uptake, we calculated the EOB enhancement ratio, which is the ratio of the relative intensity of tumorous lesion to surrounding nontumorous area on hepatobiliary phase images (post-contrast EOB ratio) to that on unenhanced images (pre-contrast EOB ratio). Portal blood flow was evaluated by CT during arterial portography.Results:Post-contrast EOB ratios significantly decreased as the degree of differentiation declined in DNs (1.00 ± 0.14) and well, moderately and poorly differentiated HCCs (0.79 ± 0.19, 0.60 ± 0.27, 0.49 ± 0.10 respectively). Gd-EOB-DTPA uptake, assessed by EOB enhancement ratios, deceased slightly in DNs and still more in HCCs, while there was no statistical difference in the decrease between different histological grades of HCC. Reductions in portal blood flow were observed less frequently than decreases in Gd-EOB-DTPA uptake in DNs and well-differentiated HCCs.Conclusions:Reduced Gd-EOB-DTPA uptake might be an early event of hepatocarcinogenesis, preceding portal blood flow reduction. The hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI may help estimate histological grading, although difficulties exist in differentiating HCCs from DNs.

[1]  M. Taupitz,et al.  Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. , 1995, Radiology.

[2]  O. Matsui,et al.  Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. , 1999, AJR. American journal of roentgenology.

[3]  D. Woodfield Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[4]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[5]  Masatoshi Tanaka,et al.  Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[6]  C. Loddenkemper,et al.  Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. , 2009, AJR. American journal of roentgenology.

[7]  H. Tsukuma,et al.  Declining Incidence of Hepatocellular Carcinoma in Osaka, Japan, from 1990 to 2003 , 2008, Annals of Internal Medicine.

[8]  M. Sherman,et al.  Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis , 2001, Gut.

[9]  J. Bruix,et al.  Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma , 2004, Hepatology.

[10]  S. D’Angelo,et al.  Contrast-enhanced sonography versus biopsy for the differential diagnosis of thrombosis in hepatocellular carcinoma patients. , 2009, World journal of gastroenterology.

[11]  T. Murakami,et al.  Potential of Gadolinium-ethoxybenzyl-diethylenetriamine Pentaacetic Acid (Gd-EOB-DTPA) for Differential Diagnosis of Nonalcoholic Steatohepatitis and Fatty Liver in Rats Using Magnetic Resonance Imaging , 2007, Investigative radiology.

[12]  J. Stachura,et al.  16,16‐Dimethyl‐PGE2 Protection Against α — Napthy lisothiocy anate – Induced Experimental Cholangitis in the Rat , 1984 .

[13]  T. Murakami,et al.  Hypervascular hepatocellular carcinoma: Combined dynamic MDCT and SPIO‐enhanced MRI versus combined CTHA and CTAP , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[14]  N. Moriyama,et al.  Early hepatocellular carcinoma: appearance at CT during arterial portography and CT arteriography with pathologic correlation. , 1995, Radiology.

[15]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[16]  Maximilian F Reiser,et al.  Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT--initial observations. , 2005, Radiology.

[17]  M. Mack,et al.  Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. , 1996, Radiology.

[18]  T. Murakami,et al.  Superparamagnetic iron oxide–enhanced magnetic resonance images of hepatocellular carcinoma: Correlation with histological grading , 2000, Hepatology.

[19]  J. Hoofnagle,et al.  NIH conference. Hepatocellular carcinoma. , 1988, Annals of internal medicine.

[20]  Yong Hwan Jeon,et al.  Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. , 2009, AJR. American journal of roentgenology.

[21]  E. Hatano,et al.  Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma , 2009, Journal of Gastroenterology.

[22]  K. Abe,et al.  Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. , 2005, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.

[23]  J. Willatt,et al.  MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. , 2008, Radiology.

[24]  S. Hirohashi,et al.  Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. , 1991, Human pathology.

[25]  I. Wanless,et al.  Terminology of nodular hepatocellular lesions , 1995 .

[26]  B. Bell,et al.  A comparison of hepatopathologists' and community pathologists' review of liver biopsy specimens from patients with hepatitis C. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[27]  Michiie Sakamoto,et al.  Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia , 2009, Hepatology.

[28]  G. D’Amico,et al.  Hepatocellular carcinoma , 1991, Digestive Diseases and Sciences.

[29]  Young Min Han,et al.  Detection of liver metastases: Gadoxetic acid-enhanced three-dimensional MR imaging versus ferucarbotran-enhanced MR imaging. , 2010, European journal of radiology.

[30]  U. Motosugi,et al.  Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: Is it possible to shorten the examination time? , 2009, European Radiology.